Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most
common type being venous thromboembolism (VTE). Several risk factors for developing …

Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …

The risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) associated
with immune checkpoint inhibitors is currently unclear. Our aim was to quantify the risk of …

The term embolic stroke of undetermined source (ESUS) was introduced in 2014 to describe
patients with a nonlacunar ischemic stroke and no convincing etiology. The terms ESUS and …

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

The 2020 update of the Canadian Stroke Best Practice Recommendations (CSBPR) for the
Secondary Prevention of Stroke includes current evidence-based recommendations and …

Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients
with cancer. Over the past 2 decades, enormous advances have been made in the …

One-quarter to one-third of ischemic strokes have no established mechanism after standard
diagnostic evaluation and are classified as embolic stroke of undetermined source (ESUS) …